Stabilizing biologicals,
especially vaccines.

Why ElarexEscape the cold chain

Proven technology

Our solution is a straightforward formulation that has been developed over the past five years at McMaster University. It offers a radical degree of temperature stabilization that has been shown to stabilize vaccines that normally require -80°C storage to be stored at 40°

Wide applicability

This technology has also been shown to be applicable to a wide array of bio-therapeutics beyond vaccines. Small molecules, enzymes, biologics, DNA and RNA can all be stabilized.

Stabilize the unstable

Extend long term stability at any temperature. Our solution can extend the stability of vaccines and biologics at refrigerator or freezer temperatures, which can be the difference between getting a product to market or shelving it.

Flexible delivery formats

Formulate in a film, powder, porous sugar glass or solution. PT120 offers a variety of options for formulation and delivery forms for your therapeutic product.

History

Dr. Filipe’s lab at McMaster University started experimenting with stabilizing vaccines and biologics in pullulan in 2014.  This breakthrough work evolved to include trehalose, and resulted in numerous publications and patents.  In 2019, Elarex Inc. was co-founded by Robert DeWitte and Carlos Filipe to bring this proprietary technology to market in the form of PT120.

PT-120 ™

Our solution is a straightforward, patented formulation that has been developed over the past five years at McMaster University.  It offers exceptional temperature stabilization that has been shown to stabilize vaccines that normally require -80°C storage to be stored at 40°C, a difference of 120 degrees.  In vivo data in mice has shown that this stabilization results in effective vaccines when stored at the higher temperature.  No freeze drying is necessary, and the process is simple, with all the components of the solution on the FDA “GRAS” list (Generally Regarded as Safe).  This differs from all the other competitors’ offerings in this field.

This technology has also been shown to be applicable to a wide array of bio-therapeutics beyond vaccines.  Small molecules, enzymes, biologics, DNA and RNA have all been shown to benefit from the stabilization offered by this technology.

Partnership

McMaster University has backed Elarex with financial and in-kind contributions.  Having been recently named Canada’s top research-intensive university, McMaster is the perfect partner for a startup in need of research expertise and facilities that would be hard to access otherwise.

“Getting our research into the hands of those who can put it to its best use is critical for us. Elarex has been a great partner in bringing investors and business expertise to help move Dr. Filipe’s technology from lab to market. Together we have the potential to make an impact in the fight against COVID-19 and other infectious diseases.” — Karen Mossman, vice-president, research, and leading virologist, McMaster University

NEWS & EVENTS

Variable volume multichannel pipette. Medical worker, scientist, laboratory assistant in rubber gloves works in the laboratory

Nationalgeographic.com

Future COVID-19 vaccines might not have to be kept so cold
https://elarexinc.com/wp-content/uploads/2021/05/Canadian-scientists-1.png

Nationalpost.com

Canadian scientists figure out how to preserve vaccines without refrigeration
https://elarexinc.com/wp-content/uploads/2021/07/grdgdrd-1.jpg

Theglobeandmail.com

Canadian scientists create stable, affordable way to transport fragile vaccines
https://elarexinc.com/wp-content/uploads/2021/05/lifesaving.png

McMaster University

McMaster University invents new life-saving vaccine method
https://elarexinc.com/wp-content/uploads/2021/07/dhtfxh-1.jpg

McMaster

McMaster researchers bringing to market invention to transport fragile vaccines without refrigeration

CONTACT US

    Name (required)*
    Email (required)*
    Phone (required)*
    Message

    Subscribe toOur Newsletter